Opioid receptor mu 1. Every medicine in our data that ChEMBL or the Guide to Pharmacology records as acting on this protein, with the source for each and its current clinical trials on this site.
| Medicine | How it acts | Source | Current trials here |
|---|---|---|---|
| Morphine CHEMBL70 |
Mu opioid receptor agonist Agonist Small molecule |
✓ Both | 42 |
| Fentanyl CHEMBL596 |
Mu opioid receptor agonist Agonist Small molecule |
✓ Both | 31 |
| Sufentanil CHEMBL658 |
Mu opioid receptor agonist Agonist Small molecule |
✓ Both | 19 |
| Remifentanil CHEMBL1005 |
Mu opioid receptor agonist Agonist Small molecule |
ChEMBL only | 17 |
| Naltrexone CHEMBL19019 |
Opioid receptors; mu/kappa/delta antagonist Antagonist Small molecule |
✓ Both | 10 |
| Oliceridine CHEMBL2443262 |
Mu opioid receptor agonist Agonist Small molecule |
ChEMBL only | 8 |
| Tramadol CHEMBL1237044 |
Mu opioid receptor agonist Agonist Small molecule |
✓ Both | 8 |
| Oxycodone CHEMBL656 |
Mu opioid receptor agonist Agonist Small molecule |
ChEMBL only | 7 |
| Buprenorphine CHEMBL511142 |
Mu opioid receptor agonist Agonist Small molecule |
✓ Both | 5 |
| Methadone CHEMBL651 |
Mu opioid receptor agonist Agonist Small molecule |
✓ Both | 5 |
| Nalbuphine CHEMBL895 |
Opioid receptors; mu/kappa/delta agonist Agonist Small molecule |
✓ Both | 5 |
| Loperamide CHEMBL841 |
Mu opioid receptor agonist Agonist Small molecule |
✓ Both | 3 |
| Meperidine CHEMBL607 |
Mu opioid receptor agonist Agonist Small molecule |
✓ Both | 3 |
| Alfentanil CHEMBL634 |
Mu opioid receptor agonist Agonist Small molecule |
ChEMBL only | 2 |
| Dezocine CHEMBL1685 |
Mu opioid receptor partial agonist Partial agonist Small molecule |
ChEMBL only | 2 |
| Hydromorphone CHEMBL398707 |
Mu opioid receptor agonist Agonist Small molecule |
✓ Both | 2 |
| Naldemedine CHEMBL2105755 |
Mu opioid receptor antagonist Antagonist Small molecule |
✓ Both | 2 |
| Naloxone Hydrochloride CHEMBL1718 |
Opioid receptors; mu/kappa/delta antagonist Antagonist Small molecule |
✓ Both | 2 |
“Both” means ChEMBL and the Guide to Pharmacology each record this medicine acting on this protein; “only” means one source records it and the other does not (often because it lists fewer secondary targets). The Guide to Pharmacology adds a medicine here only when this protein is its primary target. Medicines without a link have no page on this site yet.
| Disease | Medicines tested | Furthest trial phase |
|---|---|---|
| Opioid use disorder | 8 | Phase 3 |
| Opiate dependence | 7 | Phase 3 |
| Cancer | 6 | Phase 3 |
| Cancer pain | 6 | Phase 3 |
| Low back pain | 4 | Phase 3 |
| Osteoarthritis | 4 | Phase 3 |
| Pain | 3 | Phase 3 |
| Mucositis | 3 | Phase 3 |
| Neonatal abstinence syndrome | 3 | Phase 3 |
| Back pain | 2 | Phase 3 |
| COVID-19 | 2 | Phase 3 |
| Chronic pain | 2 | Phase 3 |
| Cough | 2 | Phase 3 |
| HIV infectious disease | 2 | Phase 3 |
| Pruritus | 2 | Phase 3 |
From ChEMBL's drug-disease records, which draw on trial registries. A trial phase is not an approval; approved uses are on each medicine's page from the regulators' own records.
Which medicines act on this protein comes from two independent, expert-curated sources: ChEMBL's mechanism-of-action records (via the Open Targets Platform) and the IUPHAR/BPS Guide to PHARMACOLOGY. Each row says which of them lists it. Data from them is shared here under their share-alike licences (CC BY-SA 3.0 and 4.0).
A job re-reads both sources every 30 days. Medicines are matched to our pages by exact name or a ChEMBL-curated synonym, and to the Guide to Pharmacology by ChEMBL ID or exact name, never by a close spelling. No AI drafting. See our methodology. The Open Targets data on this page was last retrieved on 30 Sep 2026. How every register is built: methodology · fixes we have made: corrections log.
